Raymond James raised the firm’s price target on ARS Pharmaceuticals (SPRY) to $28 from $26 and keeps a Strong Buy rating on the shares. ARS Pharmaceuticals pre-announced Q4 net sales of $6.5M, well above Street estimates, driven by increasing awareness and patient access, the analyst tells investors in a research note. Based on ARS’s disclosure that roughly 14,500 neffy 2-packs were delivered in the fourth quarter, script data implies a capture rate of about 60% this quarter, which is very low but “unsurprising” given the early stage of the launch, the firm says.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals Highlights Success and Plans for 2025
- ARS Pharmaceuticals reports 2025 key strategic priorities
- ARS Pharmaceuticals reports preliminary Q4 neffy revenue $6.5M
- ARS Pharmaceuticals files for approval of neffy in Canada, U.K.
- ARS Pharmaceuticals adds neffy to Commercial national formularies